Vandoros, Sotiris and Kanavos, Panos
The generics paradox revisited: empirical evidence from regulated markets.
Applied economics, 45
Full text not available from this repository.
Earlier studies have pointed at the presence of a generics paradox in the US prescription drug market. This article tests whether the generics paradox also holds in the presence of pricing and reimbursement regulation in six European prescription drug markets. Using proprietary pricing and market share data, the results of panel data analysis suggest that the generics paradox also holds in these markets. Neither generic entry nor generic market penetration affect prices of originator drugs downwards, and prices of originator drugs actually increase post-generic entry.
||© 2012 Taylor & Francis Group
||pharmaceuticals, price competition, patent expiry, generics paradox, panel data
|Library of Congress subject classification:
||H Social Sciences > HC Economic History and Conditions
R Medicine > RM Therapeutics. Pharmacology
|Journal of Economic Literature Classification System:
||I - Health, Education, and Welfare > I1 - Health > I18 - Government Policy; Regulation; Public Health
L - Industrial Organization > L1 - Market Structure, Firm Strategy, and Market Performance > L11 - Production, Pricing, and Market Structure; Size Distribution of Firms
L - Industrial Organization > L5 - Regulation and Industrial Policy > L52 - Industrial Policy; Sectoral Planning Methods
L - Industrial Organization > L6 - Industry Studies: Manufacturing > L65 - Chemicals; Rubber; Drugs; Biotechnology
||Departments > European Institute
Departments > Social Policy
Research centres and groups > LSE Health
Actions (login required)
||Record administration - authorised staff only